Successful recovery after an overdose of argatroban

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 336-339

  Yee, Andrew J ^a   Kuter, David J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Argatroban; Fresh frozen plasma; Overdose

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; FRESH FROZEN PLASMA; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; THROMBIN INHIBITOR; VANCOMYCIN;

AGED; ARTICLE; BLEEDING; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; CRITICAL ILLNESS; CROHN DISEASE; DRUG CLEARANCE; DRUG OVERDOSE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTESTINE FISTULA; MALE; MEDICATION ERROR; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RECTUM FISTULA;

AGED; ANTICOAGULANTS; BLOOD COMPONENT TRANSFUSION; HUMANS; MALE; MEDICATION ERRORS; OVERDOSE; PIPECOLIC ACIDS; PLASMA; THROMBIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33144478643     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G494     Document Type: Article

References (20)

1. Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolys 2002;13:41-7.
2. Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995;274:35-43.
3. Fanikos J, Stapinski C, Koo S, Kucher N, Tsilimingras K, Goldhaber SZ. Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol 2004;94:532-5.
4. Hampton T. Bar codes mandated for hospital meds. JAMA 2004;291:1685-6.
5. Package insert. Argatroban. Research Triangle Park, NC: GlaxoSmithKline, 2005.
6. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-84.
7. Knoblauch R, Pollak ES, Russell JE. Toxicity of argatroban overdose in a 65-year-old man (letter). Am J Hematol 2005;79:248-9.
8. Tran JQ, Di Cicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999;39:513-9.
9. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29.
10. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004;66:2446-53.
11. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34:25-56.
12. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4. DOI 10.1345/aph.1C187
13. Kubiak DW, Szumita PM, Fanikos JR. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1119-23. Epub 10 May 2005. DOI 10.1345/aph.1G020
14. Alperin JB. Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. JAMA 1987;258:1916-9.
15. Bosinski T, Bailie GR, Eisele G. Massive and extended rebound of serum lithium concentrations following hemodialysis in two chronic overdose cases. Am J Emerg Med 1998;16:98-100.
16. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7.
17. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-64.
18. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001;101:145-57.
19. Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004;100:443-5.
20. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981;305:717-21.